menu

Frontotemporal Dementia Treatment Market

Schedule Call

Frontotemporal Dementia Treatment Market

Frontotemporal Dementia Treatment Market by Drug Class (Cognitive Enhancers, Antipsychotics), Disease Indication (Frontotemporal Dementia, Primary Progressive Aphasia), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

GR - 268858 Category: Pharmaceuticals

Number of pages: 100  |  Report Format: PDF  |  Published date: March 31, 2023

Historical Years – 2021  |  Base Year – 2022  |  Forecasted Years – 2023-2031


Frontotemporal Dementia Treatment Market Scope

Report Attribute

Details

Market Size Value in 2022

US$ 341.1 million

Revenue Forecast in 2031

US$ 533.7 million

CAGR

5.1%

Base Year for Estimation

2022

Forecast Period

2023-2031

Historical Year

2021

Segments Covered

Drug Class, Disease Indication, Distribution Channel, and Region

Regional Scope

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global frontotemporal dementia treatment market was valued at US$ 341.1 million in 2022 and is expected to register a revenue CAGR of 5.1% to reach US$ 533.7 million by 2031.

Frontotemporal Dementia Treatment Market Fundamentals

Frontotemporal dementia is a neurodegenerative disorder that affects the frontal and temporal lobes of the brain, leading to changes in behavior, language, and personality. While there is currently no cure for frontotemporal dementia, some treatments are available that can help manage symptoms and slow down the progression of the disease. One approach to treating frontotemporal dementia involves using medications that target specific symptoms, such as antidepressants or antipsychotics. However, these medications can have significant side effects, and their effectiveness may vary depending on the individual. Another approach involves non-pharmacological treatments, such as behavioral interventions or speech therapy, which can help improve communication and manage behavioral changes. Additionally, lifestyle modifications, such as exercise and a healthy diet, also help slow the disease's progression.

While there is no cure for frontotemporal dementia, a combination of medications, non-pharmacological interventions, and lifestyle modifications can help manage symptoms and improve the quality of life for those with the disease. Individuals with frontotemporal dementia must work closely with their healthcare providers to develop a comprehensive treatment plan that addresses their needs and symptoms. 

[68556]

Frontotemporal Dementia Treatment Market Dynamics

The prevalence of frontotemporal dementia is expected to rise as the population ages. This will likely lead to an increased demand for treatments for frontotemporal dementia and related conditions. For instance, according to BioMed Central's report of January 2021, frontotemporal dementia has a prevalence rate of 0.01 – 4.61 per 1000 persons. As more people become aware of frontotemporal dementia and its symptoms, there may be greater demand for treatments that can help manage the condition and will boost the growth of the global frontotemporal dementia treatment market. Additionally, advances in imaging and other diagnostic techniques may help to identify frontotemporal dementia earlier and more accurately. This could lead to earlier interventions and a greater need for treatments. Furthermore, as understanding the underlying causes of frontotemporal dementia improves, new therapeutic strategies that target particular disease pathways may be created.

However, treatments for frontotemporal dementia can be expensive, particularly as the disease progresses and more care is required. This may limit access to treatments for those who cannot afford them. Moreover, there are no exact treatments that can cure frontotemporal dementia or slow down its progression. This may limit the demand for existing treatments and the development of new ones. Additionally, side effects of treatments, regulatory hurdles, and limited awareness of frontotemporal dementia impede the overall market growth.  

Frontotemporal Dementia Treatment Market Ecosystem

The global frontotemporal dementia treatment market is analyzed from four perspectives: drug class, disease indication, distribution channel, and region. 

Frontotemporal Dementia Treatment Market by Drug Class 

[98685]

Based on the drug class, the global frontotemporal dementia treatment market is segmented into cognitive enhancers, antipsychotics, antidepressants, CNS stimulants, and other drugs.

The antidepressants segment dominated the market with the principal revenue share in 2022. Antidepressants are one of the medications commonly used to manage symptoms in individuals with frontotemporal dementia. While they do not cure the disease, they can help alleviate some of the behavioral and psychological symptoms associated with frontotemporal dementia. Antidepressants work by altering the levels of neurotransmitters in the brain, such as serotonin, norepinephrine, and dopamine, which can help regulate mood and behavior. This results in the overall revenue share of this segment. Some commonly used antidepressants for frontotemporal dementia include selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). 

The antipsychotics segment accounted for a prominent revenue share in the market. Antipsychotic drugs are commonly used to manage the behavioral and psychological symptoms associated with the disease. Some widely used antipsychotics for frontotemporal dementia include atypical antipsychotics such as risperidone and olanzapine. The exact mechanism of action of antipsychotic medications in frontotemporal dementia is not fully understood. However, it is believed that antipsychotics work by blocking the action of dopamine in certain brain regions, which may help reduce the severity of psychotic symptoms, such as hallucinations and delusions, that some frontotemporal dementia patients may experience. Additionally, antipsychotics may also have a sedative effect that can help to calm agitation and aggression in some frontotemporal dementia patients, boosting the segment's revenue share. 

Frontotemporal Dementia Treatment Market by Disease Indication

Based on the disease indication, the global frontotemporal dementia treatment market is segmented into frontotemporal dementia, primary progressive aphasia, and moment disorders.

The frontotemporal dementia segment dominated the market with the largest revenue share in 2022. Frontotemporal dementia is a type of dementia that affects the frontal and temporal lobes of the brain, which are responsible for personality, behavior, and language. It is a progressive neurodegenerative disorder that primarily affects individuals under 65. However, it can occur in older adults as well. Frontotemporal dementia is characterized by changes in behavior, personality, and language, including inappropriate social behavior, loss of empathy, difficulty with language and communication, and a lack of insight into one's behavior. As the disease progresses, individuals with frontotemporal dementia may also experience memory loss and other cognitive impairments similar to those seen in other types of dementia. These overall factors contribute to the revenue growth of the frontotemporal dementia segment. 

Similarly, the primary progressive aphasia segment also accounts for a prominent revenue share. Primary Progressive Aphasia is a neurological disorder affecting a person's ability to communicate. It is a form of dementia that primarily affects language and speech abilities. People with progressive aphasia may have difficulty finding words, using grammar properly, and communicating effectively. This condition gradually worsens over time and can eventually lead to a complete loss of language ability. The degeneration of brain cells in the areas of the brain responsible for language and communication causes progressive aphasia. It is typically diagnosed through medical history, cognitive and language tests, and brain imaging. Treatment for progressive aphasia varies depending on the underlying cause and may include speech therapy, medication, and supportive care.

Frontotemporal Dementia Treatment Market by Distribution Channel

Based on the distribution channel, the global frontotemporal dementia treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

The hospital pharmacies segment accounts for a prominent revenue share in the frontotemporal dementia treatment market in 2022, as they play a critical role in managing and treating frontotemporal dementia. This large revenue share is due to Hospital pharmacies being responsible for dispensing medications and providing other pharmaceutical services to hospitals and other healthcare facilities, which may include medications used to manage symptoms of frontotemporal dementia. Hospital pharmacies may provide medications such as antidepressants, antipsychotics, and mood stabilizers, which can help manage specific symptoms associated with the disease. Additionally, hospital pharmacies may provide compounding services, which involve preparing customized medications tailored to the specific needs of individual patients with frontotemporal dementia. Hospital pharmacies also play a role in patient education and counseling, providing information on medication use and potential side effects and offering support and guidance to patients and their families. This can help improve medication adherence and overall patient outcomes.

Frontotemporal Dementia Treatment Market by Region

Based on region, the global frontotemporal dementia treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. 

North America dominated the global frontotemporal dementia treatment market with the largest revenue share in 2022, attributed to the key market player present in this area, fast adoption of technology, and favorable reimbursement scenarios. Additionally, companies across the region are continuously working on launching new and novel treatment methods to treat frontotemporal dementia, which is also helping in the market revenue growth. For instance, in March 2022, Alector, Inc., a company in the clinical-stage biotechnology sector focused on immuno-neurology, unveiled the results of its INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab) in frontotemporal dementia patients who possess a C9orf72 genetic mutation (FTD-C9orf72). The announcement was made at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases, a virtual and in-person event held in Barcelona, Spain. Latozinemab is a monoclonal antibody with the potential to become the first of its kind, aimed at increasing progranulin levels - a significant regulator of immune activity and lysosomal health within the brain.

  • FTD-C9orf72 patients who received latozinemab exhibited a potential delay in the disease progression compared to the control cohort, which was matched to ALLFTD. 
  • Latozinemab was administered every month for over a year and was generally well-tolerated, consistent with other study cohorts. 
  • The treatment successfully increased progranulin levels in plasma and cerebrospinal fluid (CSF) in FTD-C9orf72 patients throughout the treatment period.

Competitive Landscape

The prominent players operating in the global frontotemporal dementia treatment market are:

Strategic Developments

  • In January 2022, According to a study led by Monash University, a potential new treatment for the second most prevalent form of dementia in people under 60 was discovered. The treatment showed promising results in stabilizing escalating behavioral issues and reversing brain shrinkage caused by the disease. This is the second clinical trial to indicate that sodium selenate could potentially slow cognitive decline and neurodegenerative damage that characterizes Alzheimer's disease and dementia. The Monash Phase 1 trial, one of the few worldwide and the only one in Australia to focus on bvFTD demonstrated that sodium selenate is safe and well-tolerated for bvFTD patients for 12 months. Most patients who received sodium selenate did not exhibit any cognitive or behavioral changes, and the trial period resulted in lower rates of brain atrophy.

Frequently Asked Questions About This Report

The expected revenue CAGR of the global frontotemporal dementia market during the forecast period will be 5.1% from 2023 to 2031.

Frontotemporal dementia is a neurodegenerative disorder that affects the frontal and temporal lobes of the brain, leading to changes in behavior, language, and personality.

The prominent players operating in the global frontotemporal dementia treatment market are Johnson & Johnson Services Inc, Prevail Therapeutics, Wave Life Sciences, AstraZeneca plc, and GlaxoSmithKline plc.

The estimated market size of the global frontotemporal dementia treatment market in 2031 is US$ 533.7 million.

The side effects of treatments, regulatory hurdles, and limited awareness of frontotemporal dementia treatment are factors restricting the global market revenue growth to its full potential.

Table of Content

  1. INTRODUCTION
    1. Market Ecosystem
    2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
    3. Currency Used in the Report
  2. RESEARCH METHODOLOGY 
    1. Research Approach
    2. Data Collection Methodology
    3. Data Sources
      1. Secondary Sources 
      2. Primary Sources
    4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
    5. Market Forecasting Model
    6. Limitations and Assumptions
  3. PREMIUM INSIGHTS
    1. Current Market Trends (COVID-19 Perspective)
    2. Key Players & Competitive Positioning (2022) 
    3. Regulatory Landscape
    4. Reimbursements
  4. MARKET DYNAMICS
    1. Drivers
    2. Restraints/Challenges
    3. Opportunities
  5. GLOBAL FRONTOTEMPORAL DEMENTIA TREATMENT MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
    1. Cognitive Enhancers
    2. Antipsychotics
    3. Antidepressants
    4. CNS Stimulants
    5. Other Drugs
  6. GLOBAL FRONTOTEMPORAL DEMENTIA TREATMENT MARKET - ANALYSIS & FORECAST, BY DISEASE INDICATION 
    1. Frontotemporal Dementia 
    2. Primary Progressive Aphasia
    3. Moment Disorders 
  7. GLOBAL FRONTOTEMPORAL DEMENTIA TREATMENT MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
    1. Hospital Pharmacies
    2. Retail Pharmacies 
    3. Online Pharmacies
  8. GLOBAL FRONTOTEMPORAL DEMENTIA TREATMENT MARKET - ANALYSIS & FORECAST, BY REGION
    1. North America Frontotemporal Dementia Treatment Market
      1. North America Frontotemporal Dementia Treatment Market, by Drug Class 
      2. North America Frontotemporal Dementia Treatment Market, by Disease Indication 
      3. North America Frontotemporal Dementia Treatment Market, by Distribution Channel
      4. North America Frontotemporal Dementia Treatment Market, by Country
        1. U.S.
          1. U.S. Frontotemporal Dementia Treatment Market, by Drug Class 
          2. U.S. Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. U.S. Frontotemporal Dementia Treatment Market, by Distribution Channel
        2. Canada
          1. Canada Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Canada Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Canada Frontotemporal Dementia Treatment Market, by Distribution Channel
    2. Europe Frontotemporal Dementia Treatment Market
      1. Europe Frontotemporal Dementia Treatment Market, by Drug Class 
      2. Europe Frontotemporal Dementia Treatment Market, by Disease Indication  
      3. Europe Frontotemporal Dementia Treatment Market, by Distribution Channel
      4. Europe Frontotemporal Dementia Treatment Market, by Country/Region
        1. Germany
          1. Germany Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Germany Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Germany Frontotemporal Dementia Treatment Market, by Distribution Channel 
        2. U.K.
          1. U.K. Frontotemporal Dementia Treatment Market, by Drug Class 
          2. U.K. Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. U.K. Frontotemporal Dementia Treatment Market, by Distribution Channel 
        3. France
          1. France Frontotemporal Dementia Treatment Market, by Drug Class 
          2. France Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. France Frontotemporal Dementia Treatment Market, by Distribution Channel
        4. Spain
          1. Spain Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Spain Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Spain Frontotemporal Dementia Treatment Market, by Distribution Channel 
        5. Italy
          1. Italy Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Italy Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Italy Frontotemporal Dementia Treatment Market, by Distribution Channel 
        6. Rest of Europe 
          1. Rest of Europe Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Rest of Europe Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Rest of Europe Frontotemporal Dementia Treatment Market, by Distribution Channel 
    3. Asia Pacific Frontotemporal Dementia Treatment Market
      1. Asia Pacific Frontotemporal Dementia Treatment Market, by Drug Class 
      2. Asia Pacific Frontotemporal Dementia Treatment Market, by Disease Indication  
      3. Asia Pacific Frontotemporal Dementia Treatment Market, by Distribution Channel
      4. Asia Pacific Frontotemporal Dementia Treatment Market, by Country/Region
        1. China
          1. China Frontotemporal Dementia Treatment Market, by Drug Class 
          2. China Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. China Frontotemporal Dementia Treatment Market, by Distribution Channel 
        2. Japan
          1. Japan Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Japan Frontotemporal Dementia Treatment Market, by Disease Indication  
          3. Japan Frontotemporal Dementia Treatment Market, by Distribution Channel
        3. India
          1. India Frontotemporal Dementia Treatment Market, by Drug Class 
          2. India Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. India Frontotemporal Dementia Treatment Market, by Distribution Channel 
        4. South Korea
          1. South Korea Frontotemporal Dementia Treatment Market, by Drug Class 
          2. South Korea Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. South Korea Frontotemporal Dementia Treatment Market, by Distribution Channel
        5. Australia
          1. Australia Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Australia Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Australia Frontotemporal Dementia Treatment Market, by Distribution Channel 
        6. Rest of Asia Pacific
          1. Rest of Asia Pacific Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Rest of Asia Pacific Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Rest of Asia Pacific Frontotemporal Dementia Treatment Market, by Distribution Channel 
    4. Latin America Frontotemporal Dementia Treatment Market
      1. Latin America Frontotemporal Dementia Treatment Market, by Drug Class 
      2. Latin America Frontotemporal Dementia Treatment Market, by Disease Indication 
      3. Latin America Frontotemporal Dementia Treatment Market, by Distribution Channel 
      4. Latin America Frontotemporal Dementia Treatment Market, by Country/ Region
        1. Brazil
          1. Brazil Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Brazil Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Brazil Frontotemporal Dementia Treatment Market, by Distribution Channel 
        2. Mexico
          1. Mexico Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Mexico Frontotemporal Dementia Treatment Market, by Disease Indication  
          3. Mexico Frontotemporal Dementia Treatment Market, by Distribution Channel
        3. Argentina
          1. Argentina Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Argentina Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Argentina Frontotemporal Dementia Treatment Market, by Distribution Channel 
        4. Rest of Latin America
          1. Rest of Latin America Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Rest of Latin America Frontotemporal Dementia Treatment Market, by Disease Indication  
          3. Rest of Latin America Frontotemporal Dementia Treatment Market, by Distribution Channel
    5. Middle East & Africa Frontotemporal Dementia Treatment Market
      1. Middle East & Africa Frontotemporal Dementia Treatment Market, by Drug Class 
      2. Middle East & Africa Frontotemporal Dementia Treatment Market, by Disease Indication 
      3. Middle East & Africa Frontotemporal Dementia Treatment Market, by Distribution Channel 
      4. Middle East & Africa Frontotemporal Dementia Treatment Market, by Country/ Region
        1. GCC Countries
          1. GCC Countries Frontotemporal Dementia Treatment Market, by Drug Class 
          2. GCC Countries Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. GCC Countries Frontotemporal Dementia Treatment Market, by Distribution Channel 
        2. South Africa
          1. South Africa Frontotemporal Dementia Treatment Market, by Drug Class 
          2. South Africa Frontotemporal Dementia Treatment Market, by Disease Indication  
          3. South Africa Frontotemporal Dementia Treatment Market, by Distribution Channel
        3. Rest of Middle East & Africa
          1. Rest of Middle East & Africa Frontotemporal Dementia Treatment Market, by Drug Class 
          2. Rest of Middle East & Africa Frontotemporal Dementia Treatment Market, by Disease Indication 
          3. Rest of Middle East & Africa Frontotemporal Dementia Treatment Market, by Distribution Channel 
  9. COMPANY PROFILES         
    1. Transposon Therapeutics
      1. Business Snapshot 
      2. Products Offered
      3. Financial Details
      4. Strategic Development
    2. Alector Inc.
    3. Denali Therapeutics Inc.
    4. Pfizer Inc.
    5. Johnson & Johnson Services Inc
    6. Prevail Therapeutics
    7. Wave Life Sciences
    8. AstraZeneca plc
    9. GlaxoSmithKline plc
    10. TauRx Pharmaceuticals Ltd.
    11. Biogen Inc.

*Insights on financial performance are subject to the availability of information in the public domain

List of Tables

 

  1. Global Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million)
  2. Global Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  3. Global Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  4. Global Frontotemporal Dementia Treatment Market, by Region, 2021-2031 (US$ Million) 
  5. North America Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  6. North America Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  7. North America Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  8. North America Frontotemporal Dementia Treatment Market, by Country, 2021-2031 (US$ Million) 
  9. U.S. Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  10. U.S. Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  11. U.S. Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  12. Canada Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  13. Canada Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  14. Canada Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  15. Europe Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  16. Europe Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  17. Europe Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  18. Europe Frontotemporal Dementia Treatment Market, by Country/ Region, 2021-2031 (US$ Million) 
  19. Germany Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  20. Germany Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  21. Germany Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million)
  22. U.K. Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  23. U.K. Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  24. U.K. Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million)
  25. France Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  26. France Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  27. France Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  28. Italy Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  29. Italy Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  30. Italy Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  31. Spain Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  32. Spain Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  33. Spain Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  34. Rest of Europe Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  35. Rest of Europe Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  36. Rest of Europe Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  37. Asia Pacific Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  38. Asia Pacific Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  39. Asia Pacific Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  40. Asia Pacific Frontotemporal Dementia Treatment Market, by Country/ Region, 2021-2031 (US$ Million) 
  41. China Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  42. China Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  43. China Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  44. Japan Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  45. Japan Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  46. Japan Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  47. India Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  48. India Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  49. India Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  50. South Korea Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  51. South Korea Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  52. South Korea Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  53. Australia Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  54. Australia Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  55. Australia Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  56. Rest of Asia Pacific Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  57. Rest of Asia Pacific Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  58. Rest of Asia Pacific Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million)
  59. Latin America Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  60. Latin America Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  61. Latin America Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  62. Latin America Frontotemporal Dementia Treatment Market, by Country/ Region, 2021–2031 (US$ Million)
  63. Brazil Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  64. Brazil Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  65. Brazil Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  66. Mexico Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  67. Mexico Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  68. Mexico Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  69. Argentina Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  70. Argentina Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  71. Argentina Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  72. Rest of Latin America Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  73. Rest of Latin America Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  74. Rest of Latin America Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million)
  75. Middle East and Africa Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  76. Middle East and Africa Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  77. Middle East and Africa Frontotemporal Dementia Treatment Market, by Distribution Channel 2021–2031 (US$ Million)
  78. Middle East and Africa Frontotemporal Dementia Treatment Market, by Country/ Region, 2021–2031 (US$ Million)
  79. GCC Countries Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  80. GCC Countries Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  81. GCC Countries Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  82. South Africa Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  83. South Africa Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  84. South Africa Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million) 
  85. Rest of Middle East & Africa Frontotemporal Dementia Treatment Market, by Drug Class, 2021-2031 (US$ Million) 
  86. Rest of Middle East & Africa Frontotemporal Dementia Treatment Market, by Disease Indication, 2021–2031 (US$ Million) 
  87. Rest of Middle East & Africa Frontotemporal Dementia Treatment Market, by Distribution Channel, 2021–2031 (US$ Million)

List of Figures

 

  1. Frontotemporal Dementia Treatment Market Ecosystem  
  2. Snapshot of Global Frontotemporal Dementia Treatment Market, 2021-2031 
  3. Snapshot of Global Frontotemporal Dementia Treatment Market, by Region, 2021-2031 
  4. Global Frontotemporal Dementia Treatment Market: COVID-19 Pandemic Impact Assessment 
  5. Global Frontotemporal Dementia Treatment Market: Key Players & Competitive Positioning (2022) 
  6. Frontotemporal Dementia Treatment: Market Dynamics 
  7. Global Frontotemporal Dementia Treatment Market for Cognitive Enhancers, 2021-2031 (US$ Million) 
  8. Global Antipsychotics for Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  9. Global Antidepressants for Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  10. Global CNS Stimulants for Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million)
  11. Global Frontotemporal Dementia Treatment Market for Other Drugs, 2021-2031 (US$ Million)
  12. Global Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million)
  13. Global Frontotemporal Dementia Treatment Market for Primary Progressive Aphasia, 2021-2031 (US$ Million)
  14. Global Frontotemporal Dementia Treatment Market for Moment Disorders, 2021-2031 (US$ Million)
  15. Global Frontotemporal Dementia Treatment Market for Hospital Pharmacies, 2021-2031 (US$ Million)
  16. Global Frontotemporal Dementia Treatment Market for Retail Pharmacies, 2021-2031 (US$ Million)
  17. Global Frontotemporal Dementia Treatment Market for Online Pharmacies, 2021-2031 (US$ Million)
  18. North America Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  19. U.S. Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  20. Canada Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  21. Europe Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  22. Germany Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  23. U.K. Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  24. France Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  25. Italy Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  26. Spain Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  27. Rest of Europe Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  28. Asia Pacific Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  29. China Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  30. Japan Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  31. India Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  32. South Korea Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  33. Australia Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  34. Rest of Asia Pacific Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  35. Latin America Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  36. Brazil Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  37. Mexico Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  38. Argentina Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million)
  39. Rest of Latin America Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million)
  40. Middle East & Africa Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  41. GCC Countries Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  42. South Africa Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million) 
  43. Rest of Middle East & Africa Frontotemporal Dementia Treatment Market, 2021-2031 (US$ Million)
  44. Transposon Therapeutics Revenue from 2019 Onwards (US$ Million)
  45. Alector Inc. Revenue from 2019 Onwards (US$ Million)
  46. Denali Therapeutics Inc. Revenue from 2019 Onwards (US$ Million)
  47. Pfizer Inc. Revenue from 2019 Onwards (US$ Million)
  48. Johnson & Johnson Services Inc Revenue from 2019 Onwards (US$ Million)
  49. Prevail Therapeutics Revenue from 2019 Onwards (US$ Million)
  50. Wave Life Sciences Revenue from 2019 Onwards (US$ Million)
  51. AstraZeneca plc Revenue from 2019 Onwards (US$ Million)
  52. GlaxoSmithKline plc Revenue from 2019 Onwards (US$ Million)
  53. TauRx Pharmaceuticals Ltd. Revenue from 2019 Onwards (US$ Million)
  54. Biogen Inc. Revenue from 2019 Onwards (US$ Million)

Single User License
Single User License
Multi User License
Enterprise User License
$4,750.00
Provides access to one user only and should not be shared with other employees within the organization.
Provides access to up to five users within the department or an organization.
Provides access to all the employees in the organization. The report can also be shared with subsidiaries, sister concerns and group entities.
Grants user/users’ access to quantitative data only, which includes but is not restricted to numeric data, tables, and charts as defined by Growth+ Reports.
  • What are the significant driving and restraining factors for the Frontotemporal Dementia Treatment Market?
  • Who are the leading companies in the market?
  • Where can you find the updates on recent developments by market players?
  • When is the right time to get discounts on complete market reports?
  • Why to invest in the Frontotemporal Dementia Treatment Market?
  • How to improve your organizational performance?
  • How to shift customers towards your brand?

Recommended Reports